Yale Study: Complementary Medicine Can Shorten Cancer Survival

Cancer patients — including those with mesothelioma — who receive complementary therapy are likely to die sooner than those who use only conventional treatment, according to researchers at Yale School of Medicine. Patients receiving complementary medicine also were more inclined to forego at least one component of their conventional treatment regimen. The study was done by a team from the Yale Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine. JAMA Oncology published the study July 19. “The study was about patients who were using unproven therapies for treatment of cancer. Patients who make that decision are more likely to refuse a conventional therapy,” lead author Dr. Skyler Johnson, chief resident in radiation oncology at Yale Medicine, told Asbestos.com. “And it appears to result in an increased risk of death.” Use Complementary Therapy Carefully The same group of researchers reported a year ago that patients using alternative medicine — nonmainstream therapy used without any conventional medicine — significantly lowered survival time. Complementary medicine refers to the type that is used alongside conventional treatments. The wide spectrum of choices includes traditional Chinese medicines, vitamins, minerals and herbs, botanicals, naturopathy, homeopathy and specialized diets. In the latest study, researchers found too often patients were using the complementary medicine as a su...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Abstract The multimodal treatment of limited peritoneal metastases may improve prognosis in selected patients (pseudomyxoma peritonei, malignant peritoneal mesothelioma, colorectal, gastric and ovarian cancer) provided complete cytoreduction can be performed. Additive intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is often performed. If the treatment is undertaken in experienced (and certified) centres, associated mortality is low. Intrapleural hyperthermic chemoperfusion (HITOC) can be performed in patients with pleural malignancies, mainly for malignant pleural mesothelioma or metastases from a...
Source: Zentralblatt fur Chirurgie - Category: Surgery Authors: Tags: Zentralbl Chir Source Type: research
ConclusionsOxaliplatin-based PIPAC appears to be a safe treatment that offers good symptom control and promising survival for patients with advanced peritoneal disease.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
More than a dozen senior officials and experts at the Environmental Protection Agency urged the EPA to ban asbestos outright, a new report shows. Two internal memos obtained by the Asbestos Disease Awareness Organization and shared with the New York Times reveal the EPA’s own scientists and lawyers advised the agency to issue a complete ban of asbestos instead of the recent regulations that only restricted its domestic use. In the memos, dated Aug. 10, 2018, EPA staff members wrote that the agency “should seek to ban all new uses of asbestos because the extreme harm from this chemical substance outweighs any ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In this study, we evaluated QOL after HIPEC for peritoneal mesothelioma.MethodsThis was a prospective study performed after HIPEC for peritoneal mesothelioma between 2002 and 2015. Patients completed QOL surveys, including the Short Form-36 (SF-36), Functional Assessment of Cancer Therapy  + Colon (FACT-C), Brief Pain Inventory (BPI), and Center for Epidemiologic Studies Depression Scale (CES-D) preoperatively and at 3, 6, 12, and 24 months postoperatively.ResultsOverall, 46 patients underwent HIPEC for peritoneal mesothelioma and completed QOL surveys. Mean age was 52.8  ± 13.8 ...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: These promising preclinical results supported the transition of BAY 2287411 into a clinical phase I program in mesothelioma and ovarian cancer patients (NCT03507452). PMID: 31064781 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
This study is an important step forward in highlighting C1q as a new prognostic candidate biomarker for a range of carcinomas. Methods Oncomine Database Analysis The expression levels of C1QA, C1QB, and C1QC genes in various carcinomas were analyzed using Oncomine (www.oncomine.org), a cancer microarray database and web-based data mining platform from genome-wide expression analyses (22, 23). We compared the differences in mRNA level between normal tissue and carcinoma. The mRNA expression levels in neoplastic tissues compared to the healthy tissues were obtained as the parameters of p-value 2, and gene ranking in the t...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study we tested the clinoptilolite, chabazite, and natrolite ability to be loaded by antitumor ribonuclease binase and the cytotoxicity of the obtained complexes. We found the optimal conditions for binase loading into zeolites and established the dynamic of its release. Cytotoxic effects of zeolite-binase complexes toward colorectal cancer Caco2 cells were characterized after 24 and 48 h of incubation with cells using MTT-test. Zeolites were toxic by itselfs and reduced cells viability by 30% (clinoptilolite), 40% (chabazite), and 70% (natrolite) after 48 h of incubation. Binase complexes with clinoptilolite as we...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry. NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted. Comments must be received by July 8, 2019. “NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, an...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions This review describes how leukocyte-heparanase can be a double-edged sword in tumor progression; it can enhance tumor immune surveillance and tumor cell clearance, but also promote tumor survival and growth. We also discuss the potential of using heparanase in leukocyte therapies against tumors, and the effects of heparanase inhibitors on tumor progression and immunity. We are just beginning to understand the influence of heparanase on a pro/anti-tumor immune response, and there are still many questions to answer. How do the pro/anti-tumorigenic effects of heparanase differ across different cancer types? Does...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Mesothelioma is an aggressive cancer covering anatomic surfaces (e.g. lining of the lungs, heart, abdomen, etc.) that resists multi-modality therapies. Regional recurrence of mesothelioma from residual tumor cells prevents long-term benefits after surgical resection. Furthermore, there is no clinical consensus on intracavitary adjuvants that are effective in extending the tumor reduction effect of surgery. Researchers at the National Cancer Institute (NCI) developed a new technology that provides a localized, regional therapeutic platform to transport cancer-specific microRNA to a cancerous surface.  This nanopar...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Alternative and Complementary Therapies | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | China Health | Colorectal Cancer | Complementary Medicine | Databases & Libraries | Diets | Environmental Health | Herbs | Homeopathy | Marketing | Men | Mesothelioma | Minerals | Nutrition | PET Scan | Radiation Therapy | Radiology | Study | Vitamins | Yale